PTCY and Allo-HCT: A Deep Dive into Outcomes, Toxicities, and Patient-Centered Care

In hematopoietic cell transplantation (HCT), post-transplant cyclophosphamide (PTCY) has emerged as a vital prophylactic agent against graft-versus-host disease (GVHD), changing the landscape of allo-HCT treatment. Recent studies underscore the effectiveness of PTCY in various donor settings, highlighting its role in improving post-transplant outcomes. Despite its growing acceptance, questions about the incidence and spectrum of potential toxicities, and the nuances of PTCY's mechanism in GVHD prevention remain open. With increasing applications across diverse patient demographics, a consolidated examination of clinical outcomes and safety profiles is crucial.

This Research Topic aims to thoroughly explore the effects of PTCY on patient well-being and post-transplant outcomes in allo-HCT. A key component includes detailed analyses of toxicity profiles, risk factors, and GVHD prevention efficacy. Research will also focus on PTCY’s pharmacodynamics, impacts on endothelial health, and facilitation of immune system reconstitution. Through understanding these facets, the goal is to enhance protocol designs and improve therapeutic strategies in transplantation medicine.

This Research Topic accepts Original Research, Systematic Review, Review and Mini-Review, Policy and Practice Reviews, Clinical Trial, Classification, Technology and Code, and Cases Report.

To gather further insights in allo-HCT using PTCY-based prophylaxis, we welcome articles addressing, but not limited to, the following themes:

• Comparative outcomes based on donor types

• Detailed profiles of PTCY-associated toxicities

• Mechanisms of GVHD prevention by PTCY

• Impact of PTCY on immune reconstitution

• Studies on patient quality of life post-transplant